Related Experiment Video
Updated: Jun 20, 2026
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Targets of protective tumor immunity
1Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA. glenn_dranoff@dfci.harvard.edu
Annals of the New York Academy of Sciences
|September 23, 2009
Summary
Identifying tumor antigens is key in cancer immunology. This study found that major histocompatibility chain-related protein A (MICA) and ERp5 are immunogenic, suggesting potential therapeutic targets.
Area of Science:
- Cancer Immunology
- Immunotherapy
Background:
- Identifying tumor antigens is crucial for understanding cancer immunology and developing effective treatments.
- The clinical significance of immune responses to most tumor antigens remains poorly understood.
- Studying patients with durable responses to immunotherapy can reveal clinically relevant antigens.
Purpose of the Study:
- To identify antigens that elicit clinically significant immune recognition in cancer patients.
- To investigate the immunogenicity of major histocompatibility chain-related protein A (MICA) and ERp5.
- To explore the therapeutic potential of targeting the NKG2D pathway.
Main Methods:
- Analysis of patients achieving durable clinical benefits from immune treatments.
- Investigating the immunogenicity of major histocompatibility chain-related protein A (MICA).
- Studying the role of ERp5 in MICA shedding.
Main Results:
- The study identified major histocompatibility chain-related protein A (MICA) as an immunogenic antigen.
- ERp5, a protein disulfide isomerase, was found to be involved in MICA shedding.
- These findings highlight the importance of the NKG2D pathway in anti-tumor immunity.
Conclusions:
- Major histocompatibility chain-related protein A (MICA) and ERp5 are immunogenic and play a role in anti-tumor immune responses.
- Components of the NKG2D pathway represent promising targets for antibody-based cancer therapies.
- Further research into MICA and ERp5 could lead to novel immunotherapeutic strategies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...